SAFETY AND SURVIVAL RESULTS FROM A PHASE 1/2 TRIAL OF INTRATUMORAL AGENT INT230-6 (CISPLATIN VINBLASTINE) INDUCES IMMUNOLOGICAL CANCER CELL DEATH ALONE OR WITH PEMBROLIZUMAB IN PATIENTS WITH REFRACTORY, METASTATIC CANCERSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
SURVIVAL AND IMMUNE RESPONSE DATA FROM INTRATUMORAL INT230-6 ALONE (IT-01) AND WITH PEMBROLIZUMAB [KEYNOTE-A10] IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE AND METASTATIC SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
INTRATUMORAL INT230-6 SHOWS A FAVORABLE SAFETY PROFILE AND EARLY SIGNS OF EFFICACY IN ADVANCED SOFT TISSUE SARCOMA WITH MONOTHERAPY AND IN COMBINATION WITH IPILIMUMAB [INTENSITY IT-01; BMS#CA184-592]JOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-100OA
NOVEL INTRATUMORAL AGENT, INT230-6 INDUCES CANCER CELL DEATH, INCREASES TUMOR INFILTRATES AND RESULTS IN DURABLE BENEFIT ALONE OR IN COMBINATION WITH PEMBROLIZUMAB IN REFRACTORY PATIENTSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-090OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向